Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1371-1378

  Zhang, Bei ^a   Wang, Xueya ^a,b   Cai, Fengfeng ^a   Chen, Weijie ^a   Loesch, Uli ^c   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Nanomedicine Research Group   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apoptosis; Cisplatin resistant; Growth inhibition; Ovarian cancer; P38 MAPK; Salinomycin; Tumor xenograft

Indexed keywords

ALCOHOL; CISPLATIN; I KAPPA B KINASE ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; RESAZURIN; S 4526; SALINOMYCIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

A2780 CP CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C13 CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OV1008 CELL; OVARY CANCER; OVCAR3 CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; SKOV3 CELL; TUMOR CELLS AND CELL LINES; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRANS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874675692     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2241     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statis¬tics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Morrison J: Advances in the understanding and treatment of ovarian cancer. J Br Menopause Soc 11: 66-71, 2005.
3. Munkarah A, Chatterjee M and Tainsky MA: Update on ovarian cancer screening. Curr Opin Obstet Gynecol 19: 22-26, 2007.
4. McGuire WP III and Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89 (Suppl): S3-S8, 2003.
5. Bristow RE and Chi DS: Platinum-based neoadjuvant chemo¬therapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103: 1070-1076, 2006.
6. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
7. Kelland LR: Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 10: 413-424, 2005.
8. Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3: 537-545, 2002.
9. Harries M and Gore M: Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 3: 529-536, 2002.
10. Jansen BA, Brouwer J and Reedijk J: Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 89: 197-202, 2002.
11. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005.
12. Choi KC, Auersperg N and Leung PC: Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol 1: 71, 2003.
13. Mabuchi S, Ohmichi M, Nishio Y, et al: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004.
14. Rudin CM, Yang Z, Schumaker LM, et al: Inhibition of gluta¬thione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318, 2003.
15. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O and Hirsoe C: Salinomycin, a new polyether antibiotic. J Antibiot 27: 814-821, 1974.
16. Callaway TR, Edrington TS, Rychlik JL, et al: Ionophores: their use as ruminant growth promotants and impact on food safety. Curr Issues Intest Microbiol 4: 43-51, 2003.
17. Gupta PB, Onder TT, Jiang G, et al: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659, 2009.
18. Fuchs D, Heinold A, Opelz G, Daniel V and Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis resis¬tance in human cancer cells. Biochem Biophys Res Commun 390: 743-749, 2009.
19. Fuchs D, Daniel V, Sadeghi M, Opelz G and Naujokat C: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 394: 1098-1104, 2010.
20. Riccioni R, Dupuis ML, Bernabei M, et al: The cancer stem cell selective inhibitor salinomycin is a P-glycoprotein inhibitor. Blood Cells Mol Dis 45: 86-92, 2010.
21. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ and Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 108: 13253-13257, 2011.
22. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
23. Chergui F, Chretien AS, Bouali S, et al: Validation of a phospho¬protein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin Chem 55: 1327-1336, 2009.
24. Martin SJ and Green DR: Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 18: 137-153, 1995.
25. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell 3: 17-22, 2003.
26. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408-9421, 2005.
27. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.
28. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675, 2001.
29. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088, 2003.
30. Weir NM, Selvendiran K, Kutala VK, et al: Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6: 178-184, 2007.
31. Medema RH, Kops GJ, Bos JL and Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787, 2000.
32. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
33. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
34. Ono K and Han J: The p38 signal transduction pathway: activa¬tion and function. Cell Signal 12: 1-13, 2000.
35. Park SJ and Kim IS: The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146: 506-513, 2005.
36. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
37. Bulavin DV and Fornace AJ Jr.: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118, 2004.
38. Brozovic A, Fritz G, Christmann M, et al: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resis¬tance. Int J Cancer 112: 974-985, 2004.